摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(β-D-ribofuranosyl)-7H-pyrrolo<2,3-d>pyrimidin-2-amine | 121196-59-6

中文名称
——
中文别名
——
英文名称
7-(β-D-ribofuranosyl)-7H-pyrrolo<2,3-d>pyrimidin-2-amine
英文别名
2-amino-N7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine;2-amino-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine;(2R,3R,4S,5R)-2-(2-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)oxolane-3,4-diol
7-(β-D-ribofuranosyl)-7H-pyrrolo<2,3-d>pyrimidin-2-amine化学式
CAS
121196-59-6
化学式
C11H14N4O4
mdl
——
分子量
266.257
InChiKey
LLNFXZMJZLXTOG-FDDDBJFASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.3
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    127
  • 氢给体数:
    4
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2-amino-4-chloro-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine 在 palladium on activated charcoal ammonium hydroxide氢气 作用下, 以 甲醇 为溶剂, 反应 4.0h, 以49%的产率得到7-(β-D-ribofuranosyl)-7H-pyrrolo<2,3-d>pyrimidin-2-amine
    参考文献:
    名称:
    与7-去氮鸟苷相关的2,4-二取代的吡咯并[2,3- d ]嘧啶α-D-和β-D-呋喃核糖苷
    摘要:
    吡咯并[2,3- d ]嘧啶4a - d与5- O -[(1, 1-二甲基乙基)二甲基甲硅烷基] -2,3 - O-(1-甲基亚乙基)-α-D-核呋喃呋喃糖酰氯(5)立体选择得到保护的β-D-核苷6a - d(方案1)。相反,除少量的β-D-异头物外,β-D-卤代糖8产生相应的α-D-核苷(9a和9b)。去保护的核苷10a和11a被转化为4-取代的2-氨基吡咯并[2,3- d ]-嘧啶β-D-呋喃呋喃糖苷1。图10C,12,14,和16和到他们的α-d端基异构体,分别为(方案2)。从4b与5的反应中,分离出包含两个核碱基部分的糖基化产物7。
    DOI:
    10.1002/hlca.19900730710
点击查看最新优质反应信息

文献信息

  • Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
    申请人:——
    公开号:US20020147160A1
    公开(公告)日:2002-10-10
    The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    本发明提供了核苷化合物及其某些衍生物,这些衍生物是RNA依赖性RNA病毒聚合酶的抑制剂。这些化合物是RNA依赖性RNA病毒复制的抑制剂,可用于治疗RNA依赖性RNA病毒感染。它们特别适用于作为丙型肝炎病毒(HCV)NS5B聚合酶的抑制剂,作为HCV复制的抑制剂,以及/或用于治疗丙型肝炎感染。本发明还描述了包含这种核苷化合物的药物组合物,单独使用或与其他对RNA依赖性RNA病毒感染,特别是HCV感染有效的制剂组合使用。还公开了使用本发明的核苷化合物抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
  • Oligonucleotides having modified nucleoside units
    申请人:——
    公开号:US20040014957A1
    公开(公告)日:2004-01-22
    Disclosed are oligonucleotides and oligonucleosides that include one or more modified nucleoside units. The oligonucleotides and oligonucleosides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.
    披露的是包括一个或多个修饰核苷单元的寡核苷酸和寡核苷糖。这些寡核苷酸和寡核苷糖特别适用于作为反义剂、核酶、适配体、siRNA试剂、探针和引物,或者当它们与RNA杂交时,作为包括RNase H和dsRNase的RNA切割酶的底物。
  • NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE
    申请人:MERCK SHARP & DOHME CORP.
    公开号:US20170183373A1
    公开(公告)日:2017-06-29
    The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    本发明提供了核苷类化合物及其某些衍生物,这些化合物是RNA依赖性RNA病毒聚合酶的抑制剂。这些化合物是RNA依赖性RNA病毒复制的抑制剂,对于治疗RNA依赖性RNA病毒感染非常有用。它们特别适用于作为乙型肝炎病毒(HCV)NS5B聚合酶的抑制剂,作为HCV复制的抑制剂,和/或用于治疗丙型肝炎感染。该发明还描述了含有这种核苷类化合物的药物组合物,单独使用或与其他针对RNA依赖性RNA病毒感染,特别是HCV感染的药物一起使用。还公开了使用本发明的核苷类化合物抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
  • 2,4-Disubstituted Pyrrolo[2,3-<i>d</i>]pyrimidine α-<scp>D</scp>- and β-<scp>D</scp>-Ribofuranosides Related to 7-Deazaguanosine
    作者:Frank Seela、Tewfik Soulimane、Kann Mersmann、Thomas Jürgens
    DOI:10.1002/hlca.19900730710
    日期:1990.10.31
    Nucleobase-anion glycosylation (KOH, tris[2-(2-methoxyethoxy)ethyl]amine (TDA-1), MeCN) of the pyrrolo[2,3-d]pyrimidines 4a–d with 5-O-[(1,1-dimethylethyl)dimethylsilyl]-2,3-O-(1-methylethylidene)-α-D-ribo-furanosyl chloride (5) gave the protected β-D-nucleosides 6a–d stereoselectively (Scheme 1). Contrary, the β-D-halogenose 8 yielded the corresponding α-D-nucleosides (9a and 9b) apart from minor
    吡咯并[2,3- d ]嘧啶4a - d与5- O -[(1, 1-二甲基乙基)二甲基甲硅烷基] -2,3 - O-(1-甲基亚乙基)-α-D-核呋喃呋喃糖酰氯(5)立体选择得到保护的β-D-核苷6a - d(方案1)。相反,除少量的β-D-异头物外,β-D-卤代糖8产生相应的α-D-核苷(9a和9b)。去保护的核苷10a和11a被转化为4-取代的2-氨基吡咯并[2,3- d ]-嘧啶β-D-呋喃呋喃糖苷1。图10C,12,14,和16和到他们的α-d端基异构体,分别为(方案2)。从4b与5的反应中,分离出包含两个核碱基部分的糖基化产物7。
  • Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
    申请人:——
    公开号:US20040110717A1
    公开(公告)日:2004-06-10
    The present invention provides nucleoside derivatives which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside derivatives alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside derivatives of the present invention.
    本发明提供了一种核苷酸衍生物,其是RNA依赖性RNA病毒聚合酶的抑制剂。这些化合物是RNA依赖性RNA病毒复制的抑制剂,可用于治疗RNA依赖性RNA病毒感染。它们特别适用于作为丙型肝炎病毒(HCV)NS5B聚合酶的抑制剂,作为HCV复制的抑制剂,和/或用于治疗丙型肝炎感染。该发明还描述了含有这种核苷酸衍生物的制药组合物,单独或与其他对RNA依赖性RNA病毒感染活性的制剂结合使用,特别是HCV感染。还揭示了使用本发明的核苷酸衍生物抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
查看更多

同类化合物

羧鸟苷霉素 硫代桑吉瓦霉素 桑霉素 核苷Q 杀结核菌素5'-三磷酸酯 杀结核菌素-5'-二磷酸酯 杀结核菌素 木糖基杀结核菌素 N4-环丙基-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-2,4-二胺 7-脱氮-2'-C-乙炔腺苷 7-去氮杂肌苷 7-去氮-AMP 7-{5-O-[二甲基(2-甲基-2-丙基)硅烷基]-2,3-O-异亚丙基-beta-D-来苏呋喃糖基}-4-甲氧基-7H-吡咯并[2,3-d]嘧啶-2-胺 7-beta-D-阿拉伯呋喃糖基-7H-吡咯并[2,3-d]嘧啶-4-胺 7-[3,5-二-O-[(2,4-二氯苯基)甲基]-2-C-甲基-beta-D-呋喃核糖基]-4-氯-7H-吡咯并[2,3-d]嘧啶-2-胺 7-[3,5-二-O-[(2,4-二氯苯基)甲基]-2-C-甲基-beta-D-呋喃核糖基]-4-氯-7H-吡咯并[2,3-d]嘧啶 7-[3,5-二-O-[(2,4-二氯苯基)甲基]-2-C-甲基-beta-D-呋喃核糖基]-4-氯-5-甲基-7H-吡咯并[2,3-d]嘧啶 7-(beta-D-来苏呋喃糖基)-4-甲氧基-7H-吡咯并[2,3-d]嘧啶-2-胺 7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-4-胺 6-氯-9-(beta-D-呋喃核糖基)-7-脱氮嘌呤 5-碘代杀结核菌素 5-碘-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-4-胺 5-甲基-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-4-胺 5-溴杀结核菌素 5-氯杀结核菌素 4-氯-7-{5-O-[二甲基(2-甲基-2-丙基)硅烷基]-2,3-O-异亚丙基-beta-D-来苏呋喃糖基}-7H-吡咯并[2,3-d]嘧啶-2-胺 4-氯-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-2-胺 4-氯-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶 4-氯-7-(2-C-乙炔基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶 4-氯-5-甲基-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶 4-氨基-7-beta-D-呋喃核糖基-7H-吡咯并[2,3-d]嘧啶-5-甲醇 4-氨基-7-(2-C-甲基-beta-D-呋喃核糖基)-7H-吡咯并[2,3-d]嘧啶-5-甲腈 4-氨基-6-氯-7-[3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]吡咯并[5,4-d]嘧啶-5-甲酰胺 4-氨基-5-氰基-7-(beta-d-呋喃核糖)吡咯并[2,3-d]嘧啶 4-(甲基硫烷基)-7-(5-O-磷羧基五呋喃糖基)-7H-吡咯并[2,3-d]嘧啶 3-氨基脱氮腺苷二氯铂(II) 2-氨基-7-[(2R,3R,4S,5R)-3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]-4-氧代-1H-吡咯并[4,5-e]嘧啶-5-甲脒 2-氨基-1,7-二氢-7-beta-D-呋喃核糖基-4H-吡咯并[2,3-d]嘧啶-4-酮 (S)-4-氨基-6-溴-7-((3R,4S,5R)-3,4-二羟基-5-羟基甲基-四氢-呋喃-2-基)-7,7alpha-二氢-4aH-吡咯并[2,3-d]嘧啶-5-甲腈 ((3AR,4R,6R,6AR)-6-(4-氯-7H-吡咯并[2,3-D]嘧啶-7-基)-2,2-二甲基四氢呋喃并[3,4-D][1,3]二氧杂卓-4-基)甲醇 4-amino-7-(4-C-methyl-β-D-ribofuranosyl)-5-(thiophen-2-yl)-7H-pyrrolo[2,3-d]pyrimidine [(R)-(4-chlorophenyl)-[(2S,3S,4R,5R)-5-[4-(3,3-diethoxypropylamino)pyrrolo[2,3-d]pyrimidin-7-yl]-3,4-dihydroxytetrahydrofuran-2-yl]methyl] 4-phenylbenzoate 5-(4-amino-7-((2R,3R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)thiophene-2-carboxylic acid 4-amino-5-iodo-7-(4-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (S)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]-(4-chlorophenyl)methanol (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-6-yl]-(4-chlorophenyl)methanol 7-β-D-arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5'-phosphate 4-chloro-5-cyano-7-[(2,3,5-tri-O-benzoyl)-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 3,7-dihydro-5-(prop-1-ynyl)-7-(β-D-ribofuranosyl)-4H-pyrrolo[2,3-d]pyrimidin-4-one 5-propyn-1-yl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine